Identification of Isomeric Amino Acids In The Antigen Binding Region Of A Monoclonal Antibody By Electron Capture Dissociation

Significance of the topic

Peptide mapping by LC-MS/MS is a cornerstone analytical approach in biopharmaceutical development for verifying primary sequence and detecting post‑translational modifications of monoclonal antibodies (mAbs). Accurately distinguishing isomeric amino acids such as leucine/isoleucine and aspartate/isoaspartate in complementarity‑determining regions (CDRs) is critical because isomerization or misassignment can alter antigen binding and compromise product quality, potency and shelf‑life. Electron capture dissociation (ECD) offers complementary fragmentation chemistry to collision‑induced dissociation (CID) and can provide unambiguous isomer identification by producing diagnostic side‑chain (w‑type) and backbone (c/z) fragments.

Objectives and study overview

The study aimed to evaluate ECD‑MS/MS for differentiating isomeric residues in a tryptic peptide derived from the CDR of a therapeutic monoclonal antibody. Specifically, the authors compared CID and ECD fragmentation of a doubly charged CDR peptide to: (1) resolve coeluting isomeric forms, (2) identify leucine versus isoleucine residues, and (3) detect aspartate versus isoaspartate formation relevant for stability and quality assessment.

Methodology

Sample preparation and digestion:

• Denaturation with 3 M guanidine‑HCl in 100 mM Tris‑HCl (pH 7.5).
• Reduction with 5 mM DTT (30 min, 60 °C) and alkylation with 10 mM iodoacetamide (1 h, 37 °C).
• Trypsin digestion for 4 h at 37 °C to generate tryptic peptides.

LC conditions:

• Reversed‑phase separation on an AdvanceBio Peptide Mapping C18 column (2.1 × 150 mm, 2.7 μm) using an Agilent 1290 Infinity II Bio LC system.
• Mobile phases: water and acetonitrile, both with 0.1% formic acid.

MS/MS and data processing:

• MS acquired on an Agilent 6545XT AdvanceBio LC/Q‑TOF equipped with an Agilent Dual Jet Stream ESI source and an Agilent ExD cell for ECD fragmentation.
• Comparison of CID (typical b/y fragments) with ECD (c/z fragments and side‑chain w‑ions).
• Data analysis using Agilent MassHunter Qualitative Analysis and Agilent ExDViewer.

Instrumentation used

• Agilent 1290 Infinity II Bio LC system.
• AdvanceBio Peptide Mapping C18 column (2.1 × 150 mm, 2.7 μm).
• Agilent 6545XT AdvanceBio LC/Q‑TOF mass spectrometer.
• Agilent Dual Jet Stream ESI source and Agilent ExD cell for ECD.
• Software: Agilent MassHunter Qualitative Analysis and Agilent ExDViewer.

Main results and discussion

Chromatography and precursor observation:

• The targeted CDR tryptic peptide produced two chromatographic peaks with identical monoisotopic mass at retention times 21.1 and 21.3 min, indicating isomeric forms or modification states that co‑migrate closely.

Fragmentation comparison and diagnostic ions:

• CID spectra produced conventional b‑ and y‑ions but could not distinguish the isomeric residues reliably.
• ECD spectra generated abundant c‑ and z‑type backbone fragments and, critically, side‑chain w‑ions that are diagnostic for isomeric side chains.
• Leucine vs isoleucine: Leucine yields a secondary w‑ion by radical loss of an isopropyl group (observed as z − 43 Da), whereas isoleucine shows loss of an ethyl radical (z − 29 Da). The ECD data indicated two leucine residues in the peptide (specific positions confirmed by the corresponding w‑ions).
• Aspartate vs isoaspartate: Isoaspartate produced a characteristic z‑ion shift of −57 Da (z − 57 Da) relative to the aspartate z‑ion, whereas aspartate displayed a neutral loss of 44 Da. The peak at Rt 21.1 min showed the z − 57 diagnostic for isoaspartate, whereas the 21.3 min peak displayed the neutral loss consistent with native aspartate.

Figures and spectral summaries (textual):

• TIC and EIC traces highlighted the two isomeric peptide peaks with identical mass but slightly different retention times.
• Zoomed ECD spectra showed clear w‑ion signals for leucine at two sequence positions and a z − 57 feature confirming isoaspartate at a defined position; these features were absent in the native/aspartate form.
• Relative ion‑type abundances illustrated that ECD favored c/z and w fragments, whereas CID spectra were dominated by b/y ions.

Benefits and practical applications of the method

• Unambiguous identification of isomeric residues in CDRs improves confidence in sequence assignment and annotation of critical quality attributes for therapeutic mAbs.
• Detection of isoaspartate formation is particularly relevant for stability studies, forced‑degradation experiments and shelf‑life determination because isomerization can affect antigen binding and immunogenicity.
• ECD adds orthogonal fragmentation information to CID, enabling a more complete peptide characterization workflow without requiring laborious orthogonal chemical methods.
• Implementation supports QA/QC, comparability studies, and regulatory documentation where precise residue assignment is required.

Future trends and potential applications

• Broader adoption of electron‑based fragmentation (ECD, ETD) in routine biopharma peptide mapping workflows, potentially integrated with CID/HCD and UVPD to maximize sequence coverage and PTM localization.
• Automation and software advancement for automated detection of diagnostic w‑ions and isoaspartate signatures to streamline high‑throughput characterization.
• Application to other isomeric or labile modifications (e.g., epimerization, deamidation) and to middle‑down/top‑down approaches for intact or subunit mAb analysis.
• Integration with structural and functional assays to directly correlate chemical isomerization with binding affinity and stability, informing formulation and process decisions.

Conclusions

Electron capture dissociation coupled with high‑resolution LC‑Q‑TOF MS provides clear diagnostic fragmentation patterns that distinguish leucine versus isoleucine and aspartate versus isoaspartate in a CDR tryptic peptide where CID alone fails. The approach enables unambiguous residue assignment relevant to mAb quality, stability and function, and constitutes a powerful complementary tool for biopharmaceutical characterization and development.

References

• Poster: Identification of Isomeric Amino Acids In The Antigen Binding Region Of A Monoclonal Antibody By Electron Capture Dissociation. ASMS 2026, Poster Reprint ThP 040. Authors: G. Vandenborre et al., RIC Group and Agilent Technologies, June 2026.